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EvidEncE-basEd answErA
	 Do	annual	pelvic	exams		
benefit	asymptomatic	women	
who	receive	regular	Pap	smears?
	 	 No evidence exists	 to	 support	
	 	 a	 clinical	 benefit	 from	 annual	
pelvic	 examinations	 for	 asymptomatic	
women	 who	 receive	 Pap	 smears	 every	
3	 to	 5	 years.	 However,	 the	 American	
College	of	Obstetricians	and	Gynecologists	
(ACOG)	 committee	 on	 gynecologic	 prac-
tice	 recommends	 annual	 pelvic	 exams	
(strength	 of	 recommendation	 [SOR]:	 c,	
expert	opinion).	
Urine	testing	alone	reliably	diagnoses	
gonorrhea	 and	 chlamydia	 (SOR:	 a, sys-
tematic	review	of	cohort	studies).	
Pelvic	 examinations	 unreliably	 de-
tect	adnexal	masses	(SOR:	b,	single	cohort	
study);	 pelvic	 exams	 accompanied	 by	 ul-
trasound	fail	to	affect	outcomes	in	ovarian	
cancer	screening	(SOR:	b,	cohort	studies).	
Pelvic	 exams	 aren’t	 necessary	 before	
prescribing	oral	contraceptive	pills	(OCPs)	
(SOR:	c,	expert	opinion).	
Vulvar	 carcinoma	 has	 a	 low	 preva-
lence	and	is	usually	symptomatic	(SOR:	b,	
ecologic	study	and	a	case	series).	
Evidence summary
A	 systematic	 review	 and	 meta-analysis	
included	 29	 studies	 that	 compared	 the	
sensitivity	 and	 specificity	 of	 nucleic	 acid	
amplification	 tests	 on	 specimens	 collected	
invasively	 from	 the	 cervix	 or	 urethra	 with	
noninvasively	 collected	 urine	 specimens.1	
Studies	 included	 both	 asymptomatic	 and	
symptomatic	 patients.	 Reference	 standards	
varied	and	included	cervical	culture,	enzyme	
immunoassay,	 direct	 fluorescent	 antibody,	
ligase	chain	reaction,	and	positive	results	on	
2	of	3	nucleic	acid	amplification	assays.	
The	sensitivity	and	specificity	of	chlamydia	
and	gonorrhea	detection	didn’t	differ	between	
urine	and	cervical	specimens.	The	pooled	sen-
sitivity	 and	 specificity	 for	 polymerase	 chain	
reaction	urine	samples	were	83.3%	(95%	con-
fidence	 interval	 [CI],	 77.7%-88.9%)	 and	 99.5%	
(CI,	 99.3%-99.8%),	 respectively,	 and	 for	 cervi-
cal	samples	85.5%	(CI,	80.3%-90.6%)	and	99.6%	
(CI,	99.4%-99.8%),	respectively.1
Pelvic exams detect adnexal masses,  
but not reliably
A	prospective	 cohort	of	 127	women	under-
going	 pelvic	 surgery	 had	 preoperative	 bi-
manual	exams	under	anesthesia	to	detect	an	
adnexal	mass.2	The	gold	standard	for	detec-
tion	was	findings	at	surgery.	The	woman	had	
a	high	prevalence	(20%)	of	ovarian	masses.	
Indications	 for	 surgery	 included	 diagnosis,	
sterilization,	and	suspected	malignancy.	
When	 the	 preoperative	 bimanual	 ex-
amination	detected	a	left	adnexal	mass,	the	
odds	 of	 finding	 one	 at	 surgery	 increased	
2.8	times,	whereas	when	the	exam	was	nor-
mal	the	odds	decreased	by	0.8	(positive	pre-
dictive	value	[PPV]=0.64;	95%	CI,	0.45-0.83).	
Conversely,	 the	 preoperative	 examination	
failed	 to	 correctly	 predict	 a	 right	 adnexal	
mass	regardless	of	the	result;	the	likelihood	
ratio	 for	 both	 normal	 and	 abnormal	 right	
adnexal	examinations	was	1	(PPV=0.26;	95%	
CI,	0.12-0.47).
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An ACOG  
committee  
recommends 
annual exams, 
even though it 
found no  
evidence to  
support an  
annual pelvic 
exam for  
asymptomatic,  
low-risk  
patients.
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What about pelvic exams  
with ultrasound?
An	 investigation	 of	 transvaginal	 ultra-
sonography	 (TVUS)	 from	 November	
1987	 to	 January	 1991	 screened	 a	 cohort	 of	
1300	asymptomatic	postmenopausal	women	
for	 an	ovarian	 tumor.3	 To	be	 eligible	 for	 the	
study,	 subjects	 had	 to	 have	 been	 without	
menses	for	at	least	6	months	and	have	no	his-
tory	 of	 a	 pelvic	 tumor.	 Each	woman	 under-
went	both	a	pelvic	exam	and	TVUS.
TVUS	 found	 that	 33	 of	 the	women	 had	
abnormal	ovarian	size	and	morphology	when	
compared	 with	 normal	 standards.	 Twenty-
seven	of	 the	33,	who	had	abnormalities	 that	
persisted	 longer	 than	 1	 month,	 underwent	
exploratory	 laparotomy.	 Ovarian	 enlarge-
ment	also	was	apparent	on	clinical	examina-
tion	in	10	patients.	
Of	 the	 27	 patients	 who	 underwent	 sur-
gery,	 2	 had	 primary	 ovarian	 carcinomas.	
Significantly,	both	women	had	documented	
normal	pelvic	examinations	on	screening.
Another	cohort	trial	conducted	between	
October	1984	and	July	1987	studied	801	wom-
en	ages	40	to	70	years	who	were	at	high	risk	
for	ovarian	cancer.4	Risk	factors	included	nul-
liparity;	 symptoms	 such	as	 abdominal	pain,	
urinary	 frequency,	 or	 irregular	 bleeding;	 a	
personal	history	of	cancer;	and	a	family	his-
tory	of	ovarian,	breast,	or	endometrial	cancer.	
The	 women	 underwent	 both	 pelvic	 ex-
amination	 and	 abdominal	 ultrasound	 scan-
ning.	Fifty-one	patients	had	abnormal	pelvic	
examinations	 but	 normal	 sonograms.	 None	
of	 the	51	patients,	who	were	 followed	to	 the	
end	 of	 the	 study,	 developed	 evidence	 of	
ovarian	 carcinoma.	 Abnormal	 abdominal	
ultrasound	 scans	 in	163	patients	 resulted	 in	
3	 diagnoses	 of	 malignancy.	 The	 3	 patients	
had	normal	pelvic	examinations.			
A pelvic exam isn’t needed before  
prescribing hormonal contraception 
A	 2001	 JAMA	 literature	 review	 addressed	
pelvic	 exams	 as	 a	 prerequisite	 for	 adminis-
tering	 hormonal	 contraceptives.5	 Investiga-
tors	 identified	 consensus	 statements,	 policy	
statements,	 and	 reviews	 on	 the	 subject	 and	
contacted	 major	 health	 associations	 such	
as	 the	 World	 Health	 Organization	 for	 their	
recommendations.	
Despite	a	 lack	of	evidence,	 these	expert	
sources	 concluded	 that	 a	 pelvic	 exam	 isn’t	
necessary	 to	 identify	 conditions	 in	 which	
OCPs	are	contraindicated	(pregnancy,	breast	
cancer,	 hypertension,	 and	 thromboembolic	
disease).	Medical	history	and	blood	pressure	
measurement	provide	adequate	screening.	
Vulvar cancer is rare  
and usually symptomatic
Vulvar	 disease	 is	 uncommon	 and	 almost	
always	 symptomatic.	 The	 United	 Kingdom	
national	 cancer	 registry	 found	 an	 incidence	
of	 3.7	 per	 100,000.6	 A	 prospective	 study	 of	
102	 women	 presenting	 with	 squamous	 cell	
carcinoma	of	 the	vulva	showed	that	94%	re-
ported	a	history	of	symptomatic	vulvar	irrita-
tion.7	Eighty-eight	percent	had	had	symptoms	
for	longer	than	6	months.
Recommendations
Regarding	screening	for	gonorrhea	and	chla-
mydia,	the	United	States	Preventive	Services	
Task	Force	(USPSTF)	states	that	newer	tests,	
including	nucleic	 acid	 amplification	 tests	 of	
urine,	have	improved	sensitivity	and	compa-
rable	specificity	when	compared	with	cervi-
cal	culture.8,9
The	 USPSTF	 recommends	 against	
screening	 for	 ovarian	 cancer	 in	 general,	
(Grade	D	recommendation:	no	net	benefit	or	
the	 harms	 outweigh	 the	 benefits).	The	 Task	
Force	 states	 that	 the	 sensitivity	 of	pelvic	 ex-
amination	in	detecting	ovarian	cancer	is	un-
known	based	on	several	ultrasound	studies.10
A	 2012	 ACOG	 committee	 opinion	 rec-
ommends	that	an	annual	pelvic	examination	
remain	 a	 part	 of	 the	well-woman	 visit	 even	
though	the	committee	found	no	evidence	in	
support	of	an	annual	exam	for	asymptomatic,	
low-risk	patients.11	The	committee	notes	that	
patients	and	providers	should	discuss	the	de-
cision	to	perform	a	pelvic	exam	annually.			JFP
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